Equities

PharmaSGP Holding SE

PharmaSGP Holding SE

Actions
  • Price (EUR)23.60
  • Today's Change0.00 / 0.00%
  • Shares traded36.00
  • 1 Year change+28.96%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 07:03 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of EUR
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments413421
Total Receivables, Net9.428.307.23
Total Inventory107.004.19
Prepaid expenses------
Other current assets, total2.522.320.29
Total current assets635233
Property, plant & equipment, net1.181.570.54
Goodwill, net------
Intangibles, net667482
Long term investments1.252.080
Note receivable - long term------
Other long term assets------
Total assets131129115
LIABILITIES
Accounts payable9.928.794.52
Accrued expenses------
Notes payable/short-term debt000
Current portion long-term debt/capital leases8.168.0685
Other current liabilities, total6.525.893.02
Total current liabilities252393
Total long term debt66740.00
Total debt748285
Deferred income tax0.791.230.27
Minority interest------
Other liabilities, total0.340.170.06
Total liabilities929893
SHAREHOLDERS EQUITY
Common stock121212
Additional paid-in capital383838
Retained earnings (accumulated deficit)(11)(21)(28)
Treasury stock - common(0.29)----
Unrealized gain (loss)------
Other equity, total0.772.35--
Total equity403122
Total liabilities & shareholders' equity131129115
Total common shares outstanding121212
Treasury shares - common primary issue0.0100
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.